Isomorphic Labs Secures $5B to Push AI-Designed Drugs Toward Clinical Trials
Isomorphic Labs, the AI drug-discovery platform spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to move its drug candidates into clinical trials.
Funding Details
The round was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other participants joining. All of the company's existing backers also invested, including Alphabet's venture divisions GV and CapitalG, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
AI Drug-Design Engine Built on AlphaFold
Isomorphic Labs has developed an AI drug-design engine that deploys a suite of simulation AI models to explore various areas of chemistry and help design drugs. Building on DeepMind's breakthrough AlphaFold protein-folding AI model, the company said its program has yielded "positive preclinical results" in oncology and immunology. The lab has also struck deals with pharmaceutical giants such as Eli Lilly, Novartis, and Johnson & Johnson.
Use of Proceeds
The new funding, which follows a $2.1 billion Series B round in May, will be used to continue developing the drug-design engine and to expand into additional types of medicine.
Leadership and Nobel Recognition
The Series C marks Isomorphic's first fundraise since founder and CEO Demis Hassabis stepped down as head of DeepMind to focus on drug discovery, moving into a chairman role at DeepMind. Hassabis and then-DeepMind director John Jumper won the Nobel Prize in Chemistry for the lab's work on AlphaFold, a system that predicts the 3D structure of proteins from their genetic sequence alone.
Valuation
Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was seeking to raise funding at a $50 billion valuation.
via TechCrunch AI
